Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Notes underwriting agrmnt

AXIM BIOTECHNOLOGIES, INC. (AXIM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
06/12/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/02/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/02/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Equity Purchase Agreement, by and between the Company and Investor"
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement effective May 23, 2023, by and between the Company and Accalle, LLC a limited liability Company solely owned by Mr. Kurt Phinney"
05/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
04/17/2023 10-K Annual Report for the period ended December 31, 2022
01/27/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "TL-66 Convertible Notes Modification and Default Waiver Agreement",
"Executive Settlement Agreement dated January 23, 2023, and $250,000 convertible Executive Note attached thereto",
"MMI Convertible Note Modification and Default Waiver Agreement"
11/15/2022 10-Q/A Quarterly Report for the period ended September 30, 2022 [amend]
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/07/2022 144 Form 144 - Report of proposed sale of securities:
09/23/2022 4 Schroeder Blake (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 1,000,000 options @ $0.052, valued at $52k
09/23/2022 3 O'Rourke Peter (Director) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC.
09/23/2022 4 MALASEK ROBERT (CFO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 500,000 options @ $0.052, valued at $26k
09/23/2022 4 MALASEK ROBERT (CFO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 300,000 options @ $0.42, valued at $126k
09/23/2022 4 Cunningham Robert L (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 1,000,000 options @ $0.052, valued at $52k
09/23/2022 4 Cunningham Robert L (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 500,000 options @ $0.0126, valued at $6.3k
09/23/2022 4 Scott Timothy Richard (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 1,000,000 options @ $0.052, valued at $52k
09/23/2022 4 Scott Timothy Richard (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 500,000 options @ $0.0126, valued at $6.3k
09/23/2022 4 HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 5,000,000 options @ $0.052, valued at $260k
09/23/2022 4 HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Disposed/sold 2,000,000 options @ $0.75, valued at $1.5M
09/23/2022 4 HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 3,000,000 options @ $0.42, valued at $1.3M
09/23/2022 4 HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Bought 6,000,000 shares @ $0
09/23/2022 4 HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Granted 2,000,000 options @ $0.75, valued at $1.5M
09/23/2022 SC 13D Juniper & Ivy Corp reports a 100% stake in AXIM Biotechnologies, Inc.
09/23/2022 3 Juniper & Ivy Corp (10% Owner) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC.
09/19/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "September 15, 2022, License and Distribution Agreement by and between AXIM Biotechnologies, Inc. and Verséa Ophthalmics, LLC [Portions have been omitted]",
"About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com . About Verséa Holdings, Inc. Verséa Holdings, Inc. headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts with a combined 350+ years of experience, all committed to transforming scientific discoveries into applicable healthcare & wellness solutions that are critical to improving patients’ lives. ..."
08/31/2022 SC 13D/A Valencia Catalina reports a 12.9% stake in AXIM Biotechnologies, Inc.
08/31/2022 4 Valencia Catalina (10% Owner) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.
Txns: Bought 3,861,004 shares @ $0.0259, valued at $100k
08/31/2022 SC 13D Glycodots, LLC reports a 14.3% stake in AXIM Biotechnologies, Inc.
08/31/2022 3 Glycodots, LLC (10% Owner) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC.
08/31/2022 SC 13D Valencia Catalina reports a 14.3% stake in AXIM Biotechnologies, Inc.
08/31/2022 3 Valencia Catalina (10% Owner) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy